Brokerages have retained their ratings but highlighted concerns over the delay in semaglutide commercialisation following an API impurity issue disclosed by the company during its earnings call.
Brokerages have retained their ratings but highlighted concerns over the delay in semaglutide commercialisation following an API impurity issue disclosed by the company during its earnings call.
<iframe src="https://hindustansphere.com/embed/cluster/4b54620a6d2683675f7fc8d2ddf0f927843ebc22" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Dr Reddy's Semaglutide Delay Sparks Brokerage Divide; Kotak Calls It 'Another Dose Of Disappointment' — Check Target"></iframe>
